Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?

16 May 2025

Abstract excerpt

PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is a significant player in cardiovascular disease (CVD) and type 2 diabetes (T2D). While Lp(a) contributes to residual cardiovascular risk in T2D, lower levels paradoxically increase the risk of developing T2D. This review explores Lp(a)'s dual role in cardiometabolic disease, its association with T2D, and emerging Lp(a)-lowering therapies. RECENT FINDINGS: Large-scale...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis and Cardiovascular Diseases
Share to Lipoproteins and Cardiovascular Health
Share to Protease and Inhibitor Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40377684
DOI: 10.1097/mol.0000000000000996

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?PMID 40377684Read ↗

Lipoprotein(a)Semantic proximity Read ↗

Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular DamageSemantic proximity Read ↗

What Is Currently Understood and Remains Undiscovered regarding Lp(a) in the Context of Metabolic Syndrome?Semantic proximity Read ↗

Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) MoleculeSemantic proximity Read ↗

Lipoprotein(a): Bridging the Gap Between Screening and Treatment—A Narrative ReviewSemantic proximity Read ↗

Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Semantic proximity Read ↗

Lipoprotein(a): more interesting than ever after 50 years.Semantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.Semantic proximity Read ↗

Lipoprotein(a): new insights from modern genomicsSemantic proximity Read ↗

New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular DiseaseSemantic proximity Read ↗

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.